As Screening markers for hepatocellular Carcinoma (HCC), alpha-fetoprotein (AFP) and protein induced by an absence of vitamin K or antagonist-II (PIVKA-II) are widely used, but the sensitivity and specificity are not satisfactory cnough. Neopterin is a biological marker for increased cell-mediated immunity, but has not been fully studied on HCC. To assess the clinical significance of serum neopterin as a screcning marker for HCC, fifty-six HCC patients with hver cirrhosis (LC) and thirty-two LC patients without HCC as controls were studied. Serum neopterin level (n mol/L) was determined by immunoenzymatic assay. The sensitivity and specificity were analyzed by using ROC analysis. The mean level oi neopterin in HCC was significantly higher than that in LC (20.4 YS. 7.7 nmol/L, P<0.001). There was no significant relationship among serum AFP, PIVKA-II, and neopterin in HCC patients. Whcn the cut-off value was set at 12 n mol/L, the sensitivity and specificity of neopterin was 88% and 73%, respectively. In patients with early HCC (<3cm), the detection rate of AFP, PIVKA-II, and neopterin was 35%, 35%, and 70 %, re.spectively. When all three markers were used, 95% of all HCC patients and 90% of early HCC patients could be detected. The detection rate of neopterin was not affected by ALT level, PLT count, liver function, angiographic pattern, histology, TNM stage, and type of tumor. These findings suggests that serum neopterin can be useful as a Screening marker for HCC and makes it possible to detect HCC at its earlier stage whcn used in combination with AFP or PIVKA-II.
Introduction
its early stages (7) . However, it may be sometimcs difficult to detect diffuse-type HCC by US examination. Hepatocellular carcinoma (HCC) is one of the most In addition, the thorough Observation is often difficult common malignant diseases in East Asia, including by several patient conditions such as the existence of Japan (1) . One of the cünical characteristics of HCC is obesity or colon gas. Furthermore, the results of US that most patients with this malignant disease suffer examination depend on the equipment and the skills of from liver cirrhosis (LC) as a primary disease caused the US physician. by persistent hepatitis type B or C viral infections (2) .
Currently, alpha-fetoprotein (AFP) and protein Since there are hardly any clinical symptoms in most induced by an absence of vitamin K or antagonist-II HCC patients, its diagnosis tends to be delayed and (PIVKA-II) are widely rccognized as Screening and many patients are still detected with advanced HCC, monitoring markers for HCC (6, 8) . Although AFP is for which it is impossible to conduct radical treatthe well-known tumor marker for HCC (9) , the sensiments. Therefore, it is very important to detect HCC at tivity and specificity of the marker cannot be satisfacits early stages in patients with LC.
tory. The cut-off value for normal levels of serum AFP Abdominal ultrasound examination (US) and tumor is generally set at 20 ng/ml, but AFP often provides a markers are the typical methods recommended for false positive indication in patients with LC at this cutdctcction of early-stage HCC (3) (4) (5) (6) . The US is a nonoff value (1) . Furthermore, according to recent reports, invasive, simple and useful test for detecting HCC at less than approximately 25% of cases with small, early-stagc HCC have AFP values of inore than 400 ng/ml, which is used as a highly HCC-specific cut-off value (10) . PIVKA-II is also known as a characteristic marker for HCC (11, 12) , but no more than approximatcly 50% of HCC paticnts are said to be assessed with PIVKA-II. Recently, AFP and PIVKA-Il are often measured in combination in Order lo improve the sensicivity et" HCC deiection (8) . Thus, a marker of which sensitivity and specificity are higher, and which can delect early-stage HCC is required for Screening highrisk LC patients. Neopterin belongs to the large family of pteridines, and is one of the intermediate metabolites in the biosynthesis of tetrahydrobiopterin, which is an essential coenzyme in the hydroxylation of aromatic amino acids, from guanosin triphosphostate (13) . Neopterin is released from monocytes/macrophages under the stimulus of interferon-Y produced from activated T-cells (14) . In vivo studies revealed that the serum and urinary neopterin were reported to be increased in various disorders such as viral infections (15) , autoimmune diseases (16, 17) and graft rcjection (18) . Thereforc, neopterin has been used clinically to diagnose or monitor various diseases as a biological marker of the increased cell-mediated immunity. It has also been reported that neopterin is a useful indicator of prognosis in some malignant diseases (19) (20) (21) (22) (23) .
As for serum neopterin value as a marker for HCC, there are only a few reports on small studies (24) and its importance has not been fully evaluated. In the present study, we evaluated Ihe clinical significance of serum neopterin as a Screening marker for HCC and compared its significance with AFP and PIVKA-IL In addition, we investigated the relationship between serum neopterin value and ciinical characteristics of HCC.
Patients and methods

Patients and Controls
A total of fifty-six consecutive patients with HCC accompanied with LC (40 men and 16 women; mean age, 69 years old), who had been followed-up at Liver Unit in the First Department of Internal Medicine of Osaka Medical College Hospital during the period from December 1999 to November 2000 were enrolled in this study. Randomized thirty-two LC patients without HCC (23 men and 9 women; mean age, 65 years) who had been followed at our hospital during the same period were also studied as a control group. To establish the normal level of serum neopterin, randomized 38 healthy subjects (26 men and 12 women, mean age of 64 years) who age-and sex-matched LC patients were also studied.
The diagnosis of LC was performed by biochemical data, histologieal findings of liver biopsy, typical findings by US and abdominal computed tomographic Scan (CT) such as nodular surface, dull edge, course parenchyma and splenomegaly. The existence of liver tumor was detected by using US and/or CT, and the diagnosis of HCC was made by the typical findings of tumor staining in hepatic angiography and/or by the histology of needle biopsy under ultrasonography from liver tumor.
As for the etiology of LC with or without HCC, the definition of hepatitis B (HBV) was bascd on the finding of either the positive of serum hepatitis B surface antigen (HBsAg) or the high titer of anti-hepatitis B core (anti-HBc). The definition of hepatitis C (HCV) was based on the presence of the serum anti-hepatitis C antibody (anti-HCV) and HCV-RNA. The definition of alcohol as an etiology of LC was based on the longterm history of alcohol consumption (ethanol intakes >80g/day for >10 years). The etiology of LC without HBV, HCV, alcohol and other causes of chronic liver disease was defined as NBNC.
Biochemical liver function tests and tumor markers were checked in all patients at the beginning of the study. According to the severity of LC, all patients were graded by u.sing Child-Pugh Classification (25) based on their clinical and laboratory data.
Histologieal grading of tumor cell differentiation was evaluated according to the histologieal Classification of Edmondson and Steiner (26) using biopsy specimens of tumor tissue from some patients. The clinical or Pathologie stage of HCC was evaluated by using the TMN Classification proposed by the International Union Against Cancer and the American Joint Committee on Cancer (27, 28) . None of the patients had bacterial or other viral infection, chronic renal damage, insulin-dependent diabetes mellitus (IDDM), other malignant disease, hepatic encephalopathy, and obvious flare up of hepatitis. The patients undergoing Interferon administration or immunosuppressive iherapy were also excluded from this study. Infomied consent was obtained from each patient before entry into this study.
Radiological evaluation of HCC
The number and the distribution of intra-hepatic tumors, the presence of portal thrombosis, and the existence of ascitis were assessed by US, CT, and hepatic angiography. The size of tumor was estimated by the findings CT from the total tumor area in the largest cross section relative to the largest cross section of the entirc liver. The presence of extra-hepatic metastasis was ascertained by clinical assessments, ehest X-ray examination, US, CT, magnelic resonance imaging (MRI), and bone scintigraphy.
La ho ra to ry exa niination
The followitig biochemical parameters were measurcd by using Standard multi-channel auto chemical analyzer (Hilachi Co., Ltd., Tokyo, Japan); serum albumin, total bilirubin (T.B), asparate transaminase (AST), alanine transaminase (ALT), gamma-glutamyl transpeptidase (y-GTP). Platelet count (PLT) and Prothrombin time (PT) were also measured.
The serum Icvcls of AFP and PIVKA-II, which are widely recognized as diagnostic and monitoring markers for HCC. were assayed in each patient. Serum AFP level were measured by using available commercial radioimmunoassay (a-FETO RIABEAD, Dinabot, Tokyo). Serum PIVKA-II levels were also assayed with a commercial kit (Picolumi PIVKA-II. Ezai Co., Ltd.. Tokyo).
HBsAg and anti-HBc were assayed by using available commercial enzyme-linked immunosorbent assay (ELISA) kits (Abbott Laboratories, Abbott Park. IL. USA), and anti-HCV was assayed by using second or third generation ELISA kit (Ortho Diagnostics, Tokyo, Japan), and HCV-RNA was determined by polymerase chain reaction (PCR)-based techniques (PCR Ampitcor; Roche, Branchburg, NJ, USA).
Serum neopterin
assay Blood samples were collected at the same time of assay for tumor markers and biochemical tests, and the serum was immediately separated and stored at -30°C until the assay of neopterin. Serum level of neopterin was determined by using immunoenzymatic assay kit (NEOPTERIN Enzyme Immunoassay Kit, ImmunoBiological Laboratories GmbH, Hamburg, Germany) and its value was expressed as n mol/L.
Statistical
analysis Baseline data of patients and controls were expressed as mean ± SD or median and ranges.
Non-parametric analysis was performed as appropriate to compare the mean values of baseline characleristics between the group of HCC and LC. The Mann-Whitney U test was used in Order to compare the mean value of serum neopterin concentrations between each group. The relationship among Screening markers was analyzed by using Spcarman's rank correlation coefficient.
Neopterin is generally recognized as a non-specific biological marker. In evaluating serum neopterin as a marker for HCC, it is dcsirable to set an appropriate cut-off vaiue in order that both the sensitivity and spccificity of neopterin for HCC detection are high. Therefore, we also examined the sensitivity and spccificity of neopterin in serum for detection of HCC by means of ROC (Receiver operation characteristics) analysis.
The comparison between each Screening markers of the positive rate was evaluated by Fisher's exact test. Associations among clinical variables in patients with HCC were analyzed using Pearson's chi-square test.
A P value of < 0.05 was considered as statistically significant in this study.
Results
Clinical features of HCC patients und LC patients
Tab. 1 shows the clinical features of HCC patients and LC patients without HCC. There was no significant difference between the two groups with respect to sex, agc, the causes of LC, Child-Pugh Classification, and the hepatic function tests. The mean levels of both serum AFP and PIVKA-II of HCC patients were significantly higher than those of LC patients (AFP: P<0.001, PIVKA-II; P<0.001).
Serum level of neopterin in healthy subjects, LC patients. and HCC patients
In normal healthy subjccts, the level of serum neopterin (mean ± SD) was 4.1 ±2.1 n mol/L for the men and 4.3 ± 1.2 n mol/L for the women, respectively. There were no significant differences in the mean serum neopterin level attributable to sex or agc. thus suggesting that serum neopterin level is not influenced by gender within this age ränge. Therefore, the mean level of serum neopterin (4.2 ± 1.8 n mol/L, mean ± SD) was used as normal level.
Serum levels of neopterin (mean ± SD) in LC patients and HCC patients were 7.7 ± 3.6 and 20.4 ±10.3, respectively. The distribution of the serum neopterin levels in normal subjects, LC patients, and HCC patients were shown in Fig. 1 . The serum neopterin concentrations of HCC patients were significantly higher than that of LC patients (P<0.001), which was significantly higher than that of normal healthy subjects (P<0.001).
Relationships between serum AFP, PIVKA-II and neopterin levels There was no significant relationship between serum AFP and PIVKA-II levels in HCC patients (P=0.172). No significant relationship was also observed between serum neopterin and AFP levels, or between serum neopterin and PIVKA-II levels (AFP vs. neopterin: P=ü.580; PIVKA-II vs. neopterin: P=0.561).
Sensitivity and specificity of serum AFP
Pteridines/Vol. 15 When the cut-off value of serum AFP was regarded as 20 ng/ml, 34% in LC patients without HCC were judged AFP positive and approximately half in HCC patients were judged negative. When the cut-off value of FIVKA-II was regarded as 40 mAU/ml, 6% in LC patients without HCC were judged PIVKA-II positive and 36% in HCC patients were judged negative. There was no patient with serum AFP greater than 400 ng/ml or PIVKA-II greater than 800 mAU/ml in LC patients. In HCC patients, 16% had AFP values greater than 400 ng/ml. and approximately 30% had PIVKA-II values greater than 800 mAU/ml.
On sensitivity and specificity of both AFP and PIVKA-II by means of ROC analysis, when the AFP cut-off value was sct at 20 ng/ml, its sensitivity and specificity for HCC were 52%) and 66%, respectively. When the AFP cut-off value was set at 100 ng/ml, its sensitivity and specificity for HCC were 27% and 94%', respectively. When the PIVKA-II cut-off value was set at 40 mAU/ml, its sensitivity and specificity for HCC were 64% and 94%, respectively.
Sensitivity and specificity of serum neopterin levels as a diagnostic marker for HCC
When the cut-off value of serum neopterin was set at 14 n mol/L, 13 n mol/L and 12 n mol/L, the sensitivity at each cut-off value was 66%, 70% and 73%', respectively, and the specificity was 94%, 91% and 88%, respectively. When the cut-off value of serum neopterin was set at 12 n moI/L, the sensitivity of neopterin was the highest of the three markers. In addition, the specificity of neopterin was slightly lower than that of PIVKA-II; however, it was still quite high al approximately 90%. Therefore, we set the cul-olT value of serum neopterin at 12 n mol/L in this study. When this serum neopterin level was used as the upper limit, false positive results were obtained in 13% of LC patients without HCC and more than 70% of HCC patients had a positive neopterin value. 14 (70) 12 (60) 16 (80) 17 (85) 1 8 (90) 29 (52) 36 (64) 41 (73) 48 (86) 47 (84) 52 (92) 53 ( patients. The mean serum neopterin level of HCC patients was significantly higher than that of LC patients (P <0.001), which was significantly higher than that of normal subjects (P <0.001).
Incidence of diagnostic markers in LC patients
with and without HCC Tab. 2 shows the prevalence of positive cases of the three diagnostic markers used in combination. When Screening was conducted using AFP or PIVKA-II solely, the prevalence of positive cases in all HCC patients was approximately 50% and 60%, respectively. By contrast, when serum neopterin was used for Screening at the cut-off value of 12 n mol/L, more than 70% of the HCC patients were positive. In HCC patients with the tumor less than 3 cm in diameter, the detection rate of AFP, PIVKA-II, and neopterin were 35%, 35%, and 70%, respectively. The use of two markers was found more effective for Screening of HCC. When all three markers were used, approximately 95% of all HCC patients wcrc assessed as positive and more than 90% of HCC patients with the tumor iess than 3 cm in diameter could be detected in this study.
Prevalence of diagnostic markers in relation ta clinical variables in patients with HCC
Tab. 3 shows the prevalence of positive results of three markers in relation to various clinical variables in HCC patients. The neopterin values in patients with HCC were not correlated with the changes in AST or PLT levels, and the prevalence of positivity of neopterin was irrelevant for the degree of ALT and PLT levels. The positive rate between three markers could not recognize the significant difference on Child-Pugh Classification. The detection rate of neopterin in HCC patients was similarly high (approximately 70 to 80 %) regardless of angiographic pattern, tumor histology, TNM Stage, and tumor type. The prevalence of positivity was proportional to the total tumor volume for AFP or PIVKA-II, but the prevalence of neopterin positivity was over 80% even if HCC volume was less than 5 cm. (56) 27 (75) 12 < (20) 10 (50) 16 (80) 14 (70) Child-Pugh Class 0.6801
A (32) 18 (56) 21 (66) 23 (72) B (22) 19 (46) 13 (59) 23 (72) C (2) 1 (50) 2 (100) 1 (50) Etiology 0.5399
HCV (46) 26 (57) 30 (65) 37 (80) Others (5) 1 (20) (23) 12 (52) 11 (48) 19 (83) 5cm < < 50% (24) 11 (46) 18 (75) 14 (59) 50 % < (9) 6 (66) 7 (78) 8 (89) The values represenl number with the percentage in parentheses.
Discussion
In this study, it was found that the sensitivity of detection for HCC by using serum neopterin values was higher than that by using AFP or PIVKA-II. In addition, there was no correlation between the serum neopterin leve! and the serum AFP or PIVKA-II level.
It is therefore suggested that neopterin is a clinicaily useful marker in Screening HCC if used in combination with AFP or PIVKA-II because high Icvcls of sensitivity and specificity become possible.
An important aspect as a Screening marker is whether it is highly sensitive and specific to the targct tumor. Serum AFP level sometimes incrcase in patients with LC. and ihus false positive is a problem in using AFP as a marker for HCC. It has been reported Ihat approximatcly 20% of palients with chronic hepatitis, and 50% of LC patients have increased serum AFP value (1). Although PIVKA-Il is more HCC specific and shows less false positive results than AFP does (8) , it has been reported that not more than 50% of HCC patients are PlVKA-lI positive. In the present study, the validity of neopterin as a Screening marker for HCC was evaluated. The upper Hmit of normal ränge of serum neopterin level in LC palients was set at 12 n mol/1, because neopterin is a non-specific biological marker that reflects an increased ccll-mediated immunity (14, 18) . When the cut-off value was set at this value, the prevalence of positivity of serum neopterin was higher than that of serum AFP and PIVKA-IL The sensitivity and specificity of neopterin was not only higher than those of AFP, but also higher than the sensitivity of PIVKA-II. Thus, it was suggested that neopterin would be a usefu! Screening marker for HCC.
Another important problem of conventional Screening markers for HCC is that the prevalence of positivity is low in patients with early-stage HCC (I). It was reported that 64% of palients with small HCC did not show increased serum AFP level (29) . In the patients with HCC, all three markers tended to increase with an increase in the diameter, the occupancy rate, or the number of tumors. However. the prevalencc of positis'-ity of serum neopterin was high in many patients with reiatively early stage HCC catcgorized as Stage I or II by TNM Classification as well as in those with advanced HCC classified as Stage III or IV, In addition, mosi patients with single-type HCC less than 3 cm were neopterin positi\'e (10%), which is significantly high compared to the positivity of AFP (35%) and PIVKA-II (35%). These results suggest that serum neopterin will make it possible to detecl reiatively early stage HCC.
In regard to the relationship between these three markers, there were no correlation between AFP and PIVKA-II, as previously reported (8) . It should be noted that neopterin also did not show any correlation with AFP or PIVKA-II in our study. This result shows that the sensitivity of detection for HCC may increase if all three markers are examined because sensitivity and specificity are improved due to (he complementary effects. In fact, by testing all three markers, the sensitivity and specificity increased to 95% and 100%, respectively, in the present study. In addition, the sensitivity for detection of HCC less than 3 cm increased to 90% when all three markers were used. These findings indicate that the test of serum neopterin in combination with other tumor markers will be clinically useful for Screening or Observation of HCC high-risk patients.
The neopterin values in patients with HCC were not influenced by the changes in ALT level or PLT level. The ALT value and PLT level in chronic liver disease indicate indirectly the degree of activity and fibrosis, respectively. In addition, the neopterin values was not affccted either by the score on Child-Pugh Classification. Therefore, the results in the present study suggested that neopterin could become a marker for HCC, which is not influenced by the degree of inflammation activity, hepatic fibrosis, or hepatic function of LC.
In general, it is said that the most of hypervascular HCC in angiography are of advanced type, and are poorly to moderately differentiated HCC pathologically. On the other hand, many of the hypovascular HCC are well-differentiated or early-stage HCC. In the present study, the high prevalence of positivity of serum neopterin (approximately 80%) was noted not only in the patients with hypervascular HCC but also in the patients with hypovascular HCC. In addition, the patients with well-differentiated HCC similarly showed the high prevalence of positivity in serum neopterin even in the patients with poorly to moderately differentiated HCC, although the number of patients in whom the tumor was examined histologically was small. These results show that neopterin may also become a usefui marker regardless of histopathology or angiographic findings in the HCC patients. On the relevance to the degree of malignancy and serum neopterin level. it is necessary to examine in large number of cases in future.
Increased amounts of neopterin are released by human monocytes/macrophages upon Stimulation with various cytokines such as interferon-y by activated T-cells (14) . It is thought that the increase in serum neopterin in patients with malignant tumors is related not due to the production and emission of neopterin by canccr cells themselvcs, but due to the chronic activation of cellular immunity responding to the presence of malignant tumors. Thus, neopterin is recognized as a biological or chemical marker, and is different from other substances generally recognized as tumor markers (13) . On the direct causal relation between production of neopterin and growth of malignant tumor, some observations (30, 31) have suggested that the formation of neopterin is linked with the cytotoxic repertoire of activated macrophages. They also suggested ihal neopterin modulates toxicity mediated by reactivc oxygen intermediates, which have been frequently implicated in the Initiation and promotion pf carcinogenesis. Furthermore, ii) vitro studies have shown that neopterin and 7,8-dihydroneopterin significantly induce c-fos gene expression in rat NIH3T3 fibroblasts (32) . Thus, neopterin derivatives may even promote the growth and progress of malignant tumor. There have been some clinical reports that neopterin in serum or urine is useful as a significant and independent predictor of survival in various malignant diseases. In the future, it is necessary to clarify the relation between serum neopterin level and the long-term prognosis of patients with HCC in large population.
In conclusion, the sensitivity of detection for HCC by using serum neopterin as a Screening marker was higher than that by AFP or PIVKA-II. There was no significant relationship among these markers, and more than 90% of HCC patients including the early stage HCC could be detected when all three markers were used. It is therefore suggested that serum neopterin could increase the sensitivity in Screening HCC when used in combination with AFP or PIVKA-II.
